The Potential of the Nose-to-Brain Delivery of PACAP for the Treatment of Neuronal Disease

Asma Cherait; William A Banks; David Vaudry

doi:10.3390/pharmaceutics15082032

The Potential of the Nose-to-Brain Delivery of PACAP for the Treatment of Neuronal Disease

Pharmaceutics. 2023 Jul 28;15(8):2032. doi: 10.3390/pharmaceutics15082032.

Authors

Asma Cherait^{1

2

3}, William A Banks^{4

5}, David Vaudry^{1

6}

Affiliations

¹ Univ Rouen Normandie, Inserm U1245, Medical Faculty, Normandie Univ, F-76000 Rouen, France.
² Department of Second Cycle, Higher School of Agronomy Mostaganem, Mostaganem 27000, Algeria.
³ Laboratory of Cellular Toxicology, Department of Biology, Faculty of Sciences, University of Badji Mokhtar Annaba, B.P. 12, Annaba 23000, Algeria.
⁴ Geriatric Research Educational and Clinical Center, Veterans Affairs Puget Sound Health Care System, Seattle, WA 98108, USA.
⁵ Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA.
⁶ Univ Rouen Normandie, Inserm US51, Regional Cell Imaging Platform of Normandy (PRIMACEN), Sciences and Technologies Faculty, Normandie Univ, F-76000 Rouen, France.

Abstract

Research on the neuroprotective effect of pituitary adenylate cyclase-activating polypeptide (PACAP) and its use as a therapeutic agent has grown over the past 30 years. Both in vitro and in vivo experiments have shown that PACAP exerts a strong neuroprotective effect in many central and peripheral neuronal diseases. Various delivery routes have been employed from intravenous (IV) injections to intracerebroventricular (ICV) administration, leading either to systemic or topical delivery of the peptide. Over the last decade, a growing interest in the use of intranasal (IN) administration of PACAP and other therapeutic agents has emerged as an alternative delivery route to target the brain. The aim of this review is to summarize the findings on the neuroprotective effect of PACAP and to discuss how the IN administration of PACAP could contribute to target the effects of this pleiotropic peptide.

Keywords: apoptosis; cerebral plasticity; inflammation; intranasal delivery route; neuronal diseases; neuroprotection; pituitary adenylate cyclase-activating polypeptide; redox state.

Publication types

Review

Grants and funding

A.C. was recipient of an Erasmus Mundus fellowship from the European Commission (Battuta project BT16PD3454). This research was funded by Inserm, Rouen University and the Normandy region.